文献速递白血病淋巴瘤造血干细胞移植与细胞治疗

重定向T细胞以根除B细胞急性淋巴细胞白血病:双特异性T细胞衔接器与嵌合抗原受体

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
PubMed 文献 · Leukemia · 2016-12-28

本文综述了利用双特异性T细胞衔接器(BiTE)和嵌合抗原受体(CAR)T细胞治疗复发/难治性急性淋巴细胞白血病(r/r ALL)的机制与进展。blinatumomab和CD19-CAR在CD19阳性r/r ALL中显示出令人鼓舞的缓解率,可能作为确定性治疗或桥接异基因造血细胞移植。文章讨论了独特毒性和耐药机制的管理挑战,以及优化治疗分层的方向。

要点

  • BiTE和CAR通过物理连接T细胞与肿瘤细胞激活细胞溶解信号通路,绕过肿瘤细胞耐药机制。
  • blinatumomab和CD19-CAR在CD19阳性r/r ALL中显示出令人鼓舞的缓解率。
  • 这些免疫疗法可能作为确定性治疗或桥接异基因造血细胞移植。

核心结论

  • blinatumomab和CD19-CAR在CD19阳性r/r ALL中显示出令人鼓舞的缓解率,提示它们可能作为确定性治疗或桥接异基因造血细胞移植。
  • 随着这些免疫疗法的引入,出现了与独特毒性和耐药途径相关的新挑战。
  • 对精确作用机制和免疫耐药、与其他新药潜在组合的相互作用以及制造工艺优化的深入理解,将有助于改善r/r ALL中的免疫治疗结局。

研究设计与样本

  • 综述,检索范围未在原文中报告。

主要发现

  • BiTE和CAR均绕过典型的肿瘤细胞耐药机制(如T细胞受体特异性、抗原加工和呈递、主要组织相容性复合体背景),使患者体内几乎所有细胞毒性T细胞均可被 engagement。
  • blinatumomab和CD19-CAR在CD19阳性r/r ALL中显示出令人鼓舞的缓解率。
  • 正在积累关于如何预测、预防和管理这些独特毒性的知识,以帮助更好地分层患者风险并定制治疗以最小化严重不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent advances in antibody technology to harness T cells for cancer immunotherapy, particularly in the difficult-to-treat setting of relapsed/refractory acute lymphoblastic leukemia (r/r ALL), have led to innovative methods for directing cytotoxic T cells to specific surface antigens on cancer cells. One approach involves administration of soluble bispecific (or dual-affinity) antibody-based constructs that temporarily bridge T cells and cancer cells. Another approach infuses ex vivo-engineered T cells that express a surface plasma membrane-inserted antibody construct called a chimeric antigen receptor (CAR). Both bispecific antibodies and CARs circumvent natural target cell recognition by creating a physical connection between cytotoxic T cells and target cancer cells to activate a cytolysis signaling pathway; this connection allows essentially all cytotoxic T cells in a patient to be engaged because typical tumor cell resistance mechanisms (such as T-cell receptor specificity, antigen processing and presentation, and major histocompatibility complex context) are bypassed. Both the bispecific T-cell engager (BiTE) antibody construct blinatumomab and CD19-CARs are immunotherapies that have yielded encouraging remission rates in CD19-positive r/r ALL, suggesting that they might serve as definitive treatments or bridging therapies to allogeneic hematopoietic cell transplantation. With the introduction of these immunotherapies, new challenges arise related to unique toxicities and distinctive pathways of resistance. An increasing body of knowledge is being accumulated on how to predict, prevent, and manage such toxicities, which will help to better stratify patient risk and tailor treatments to minimize severe adverse events. A deeper understanding of the precise mechanisms of action and immune resistance, interaction with other novel agents in potential combinations, and optimization in the manufacturing process will help to advance immunotherapy outcomes in the r/r ALL setting.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Aldoss I, Bargou RC, Nagorsen D, et al. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors. Leukemia. 2016. PMID: 28028314. doi:10.1038/leu.2016.391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。